Targeting HIF as a Promising Approach to Synergize With Immune Checkpoint Inhibitors
Blocking tumor hypoxia alongside immunotherapy shows mechanistic promise to overcome resistance in solid cancers, supporting near-term clinical trials.
This comprehensive review synthesizes the mechanistic rationale for combining HIF inhibitors with immune checkpoint inhibitors, demonstrating that HIF-mediated immunosuppression is a central driver of ICI resistance in solid tumors and that multiple approved/investigational HIF inhibitors can potentially reshape the tumor immune microenvironment. While primarily a review of preclinical and early clinical evidence, it provides a clear framework for combination therapy trials in hypoxic solid tumors.
What the study was
- Study design
- Narrative/systematic review
- Population
- Solid tumor patients (hypoxic tumor microenvironment); multiple cancer types
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Cancer
Why it surfaced
Timely review consolidating mechanistic rationale for HIF+ICI combination; directly relevant to the large ICI-resistant solid tumor population; clear path to near-term clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.